BG107093A - Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер - Google Patents

Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер Download PDF

Info

Publication number
BG107093A
BG107093A BG107093A BG10709302A BG107093A BG 107093 A BG107093 A BG 107093A BG 107093 A BG107093 A BG 107093A BG 10709302 A BG10709302 A BG 10709302A BG 107093 A BG107093 A BG 107093A
Authority
BG
Bulgaria
Prior art keywords
day
dose
galantamine
dosage
treatment
Prior art date
Application number
BG107093A
Other languages
Bulgarian (bg)
English (en)
Inventor
Wim Louis PARYS
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG107093A publication Critical patent/BG107093A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG107093A 2000-04-03 2002-09-12 Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер BG107093A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
BG107093A true BG107093A (bg) 2003-06-30

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107093A BG107093A (bg) 2000-04-03 2002-09-12 Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер

Country Status (20)

Country Link
EP (1) EP1272192A2 (sk)
JP (1) JP2003528913A (sk)
KR (1) KR20020086911A (sk)
CN (1) CN1430514A (sk)
AU (2) AU6584401A (sk)
BG (1) BG107093A (sk)
BR (1) BR0109770A (sk)
CA (1) CA2310926C (sk)
CZ (1) CZ20023543A3 (sk)
EE (1) EE200200554A (sk)
HR (1) HRP20020778A2 (sk)
HU (1) HUP0300566A3 (sk)
IL (1) IL152061A0 (sk)
MX (1) MXPA02009777A (sk)
NO (1) NO20024746L (sk)
PL (1) PL361272A1 (sk)
RU (1) RU2002129298A (sk)
SK (1) SK15422002A3 (sk)
WO (1) WO2001074339A2 (sk)
ZA (1) ZA200207935B (sk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
BRPI0412919A (pt) 2003-07-25 2006-09-26 Hoffmann La Roche combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
MX2010010460A (es) 2008-03-27 2010-12-15 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
EP3297632A4 (en) * 2015-05-18 2019-01-16 Synaptec Development LLC GALANTAMINE ELIMINATION OF AMYLOIDSS
WO2023036105A1 (zh) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
HUP0104778A3 (en) * 1998-12-24 2004-05-28 Janssen Pharmaceutica Nv Controlled release galantamine composition
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Also Published As

Publication number Publication date
PL361272A1 (en) 2004-10-04
EP1272192A2 (en) 2003-01-08
AU2001265844B2 (en) 2005-04-14
MXPA02009777A (es) 2003-03-27
HUP0300566A3 (en) 2004-10-28
AU6584401A (en) 2001-10-15
KR20020086911A (ko) 2002-11-20
BR0109770A (pt) 2003-02-04
NO20024746D0 (no) 2002-10-02
CZ20023543A3 (cs) 2003-03-12
CA2310926A1 (en) 2000-10-04
JP2003528913A (ja) 2003-09-30
ZA200207935B (en) 2004-01-30
EE200200554A (et) 2004-04-15
RU2002129298A (ru) 2004-03-27
HRP20020778A2 (en) 2004-04-30
IL152061A0 (en) 2003-05-29
NO20024746L (no) 2002-11-28
SK15422002A3 (sk) 2003-04-01
WO2001074339A2 (en) 2001-10-11
CN1430514A (zh) 2003-07-16
HUP0300566A2 (hu) 2003-06-28
CA2310926C (en) 2002-10-15
WO2001074339A3 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US20210283094A1 (en) Combination therapy using low-dose doxepin for the improvement of sleep
Simon et al. Cough and ACE inhibitors
US20030139391A1 (en) Efficacious dosage regimen of galantamine that reduces side effects
BG107093A (bg) Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер
KR20020075797A (ko) 엔도텔린 유발성 질환 치료제
Bachert et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
US12023315B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
US20220168286A1 (en) Treatment of raynaud's disease
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
WO2005011736A1 (ja) アルツハイマー病の予防および／または治療剤
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US20240148709A1 (en) Methods of treating eye pain and eye disorders
CA2310990A1 (en) A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
WO2022238884A1 (en) Dosing regimens
WO2009051922A1 (en) Methods of treating alzheimer's disease with (+) - isopropyl 2-methoxyethyl 4-(2-chloro-3- cyano-phenyl) -1, 4-dihydro-2, 6-dimethyl-pyridine-3, 5-dicarboxylate and a cholinesterase inhibitor